Second Sight Medical Products Inc
EYESW · NASDAQ
12/31/2024 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 23.68 | 4.69 | 0.04 |
| FCF Yield | -176.60% | -0.11% | -245.96% | -478.73% |
| EV / EBITDA | -0.53 | 6.82 | -0.40 | 0.08 |
| Quality | ||||
| ROIC | -66.83% | -0.01% | -974.87% | -343.77% |
| Gross Margin | 0.00% | 50.00% | 50.00% | 36.31% |
| Cash Conversion Ratio | 0.89 | 1.03 | 1,130.51 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -95.75% | -94.75% | -24.86% |
| Free Cash Flow Growth | 0.00% | 99.95% | 39.01% | 6.18% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | 7.76 | 0.07 | 0.26 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 2.09 |
| Cash Conversion Cycle | 0.00 | -1,457,192.31 | -354,780.00 | 38.29 |